Screening for Postmenopausal Osteoporosis: Summary of the Evidence, Table 5. Screening for Osteoporosis in 10,000 Postmenopausal Women

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force (USPSTF) > Guide to Clinical Preventive Services, 2001-2004 > Screening: Osteoporosis > Summary of the Evidence

Table 5. Screening for Osteoporosis in 10,000 Postmenopausal Women¹

Hip and Vertebral Fracture Outcomes by 5-year Age Intervals

Variable		Age Group
Variable		50-54 y	55-59 y	60-64 y	65-69 y	70-74 y	75-79 y
Base Case Assumptions²	Prevalence of osteoporosis	0.0305	0.0445	0.065	0.120	0.2025	0.285
	Relative risk for hip fracture with treatment	0.63	0.63	0.63	0.63	0.63	0.63
	Relative risk for vertebral fracture with treatment	0.52	0.52	0.52	0.52	0.52	0.52
	Adherence to treatment	0.7	0.7	0.7	0.7	0.7	0.7
Results	Identified as high-risk (osteoporotic)	305	445	650	1,200	2,025	2,850
	Hip fractures prevented	1	2	5	14	39	70
	NNS to prevent 1 hip fracture	7,446	4,338	1,856	731	254	143
	NNT to prevent 1 hip fracture	227	193	121	88	51	41
	Vertebral fractures prevented	5	7	22	40	95	134
	NNS to prevent 1 vertebral fracture	1,952	1,338	458	248	105	75
	NNT to prevent 1 vertebral fracture	60	60	30	30	21	21

¹NNS = number needed to screen for benefit; NNT = number needed to treat.
²Estimates for assumptions include age-specific prevalence rates for osteoporosis and probabilities of fractures; relative risk of 0.63 for hip fractures and 0.52 for vertebral fractures with treatment; treatment adherence of 0.7 (see text).

Formulas for calculations are described in Appendix Table 2.

Return to Document

Table 5. Screening for Osteoporosis in 10,000 Postmenopausal Women1

Hip and Vertebral Fracture Outcomes by 5-year Age Intervals

Table 5. Screening for Osteoporosis in 10,000 Postmenopausal Women¹